IMUNON to Report Topline Results from the Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer Tomorrow
29 Julio 2024 - 3:05PM
IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage
development with its DNA-mediated immunotherapy, will issue a news
release announcing topline results from the Phase 2 OVATION 2 Study
with IMNN-001 in patients with advanced ovarian cancer tomorrow,
July 30, at approximately 8:00 a.m. Eastern time, and will host an
investment community conference call to discuss the results and
answer questions at 8:30 a.m. Eastern time. IMNN-001 is the
Company’s interleukin-12 (IL-12) immunotherapy based on its
TheraPlas™ technology.
To participate in the conference call, please
dial 833-816-1132 (Toll-Free/North America) or 412-317-0711
(International/Toll) and ask for the IMUNON call. A live webcast of
the call will be available here.
Participants are encouraged to preregister for
the call here.
The call will be archived for replay through
August 13, 2024. The replay can be accessed at 877-344-7529 (U.S.
Toll-Free), 855-669-9658 (Canada Toll-Free) or 412-317-0088
(International Toll), using the replay access code 7783601. A
webcast of the call will be available here for 90 days.
About IMUNON
IMUNON is a clinical-stage biotechnology company
focused on advancing a portfolio of innovative treatments that
harness the body’s natural mechanisms to generate safe, effective
and durable responses across a broad array of human diseases,
constituting a differentiating approach from conventional
therapies. IMUNON is developing its non-viral DNA technology across
its modalities. The first modality, TheraPlas®, is developed for
the coding of cytokines and other therapeutic proteins in the
treatment of solid tumors where an immunological approach is deemed
promising. The second modality, PlaCCine®, is developed for the
delivery of DNA-coded viral antigens that can elicit a strong
immunological response.
The Company’s lead clinical program, IMNN-001,
is a DNA-based immunotherapy for the localized treatment of
advanced ovarian cancer currently in Phase 2 development. IMNN-001
works by instructing the body to produce safe and durable levels of
powerful cancer-fighting molecules, such as interleukin-12 and
interferon gamma, at the tumor site. Additionally, the Company has
entered a first-in-human study of its COVID-19 booster vaccine
(IMNN-101). IMUNON will continue to leverage these modalities and
to advance the technological frontier of plasmid DNA to better
serve patients with difficult-to-treat conditions. For more
information, please visit www.imunon.com.
Contacts:
IMUNON |
LHA Investor Relations |
David Gaiero |
Kim Sutton Golodetz |
978-376-6352 |
212-838-3777 |
dgaiero@imunon.com |
kgolodetz@lhai.com |
# # #
Imunon (NASDAQ:IMNN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Imunon (NASDAQ:IMNN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024